Digital health company PneumoWave appoints Dr Gary Cooney as Mental Health Lead as it targets respiratory depression among patients taking opioids
Digital health company PneumoWave today announced the appointment of Dr Gary Cooney as Mental Health Lead, with responsibility for the planning and execution of addiction and other mental health-related treatment studies using PneumoWave’s technology platform for diagnosis and monitoring of respiratory changes.
Gary is a medical doctor and consultant psychiatrist with extensive experience working with addiction and mental health issues in the NHS and private sector. Following a BA at Harvard, Gary studied medicine at Edinburgh University.
“Gary brings extensive expertise in the field of psychiatry as we seek to integrate our technology into routine use within addictions and mental health treatment programs” said CEO Bruce Henderson. “He will also contribute significantly to the review of datasets from our clinical research program, now underway in Dundee, Glasgow and King’s College, London, as we evaluate both physiological and behavioural data outputs to develop highly effective and easy to use solutions to reduce deaths from opioids.”
About PneumoWave:
PneumoWave is a development stage digital health company based in Scotland and the US. The company’s proprietary digital technology provides real-time physiological data and patient-centric digital biomarkers with the core focus of preventing deaths and reducing hospital admissions from respiratory causes. Performance characteristics are not yet established.
MEDIA CONTACT:
Richard Hayhurst, RHA PR
Tel +44 (0) 7711 821 527
richard@rhapr.eu
